All companies › LYCA

LYCA · Lycia Therapeutics, Inc.

Everything on this page is public record — SEC Form 4 filings and congressional disclosures — alongside any INSIDER SCANNER research case for this company.

Open-market buys6
Open-market sells0
Total purchased$37,653,863
Unique insiders buying1
Avg price paid$18.41
Research cases0
Last filing2026-10-27

Average price paid is weighted by shares, so a large purchase counts for more than a small one. It is what insiders reported paying, not a target or a fair value.

Insider flow: Buying only — a count of disclosed transactions, not a rating or a recommendation.

Insider transaction timeline

Every reported transaction, positioned by trade date. Purchases sit above the axis, sales below; circle area is proportional to dollar value. No share-price line is drawn — this feed carries transaction prices only, and a price history inferred from them would imply market data the filings do not contain.

Open-market purchase Open-market sale
2026-10-23 — Venrock Healthcare Capital Partners III, L.P. · bought 24,560 @ $25.68 2026-10-23 — Venrock Healthcare Capital Partners III, L.P. · bought 28,379 @ $26.11 2026-10-26 — Venrock Healthcare Capital Partners III, L.P. · bought 1,944,444 @ $18.00 2026-10-26 — Venrock Healthcare Capital Partners III, L.P. · bought 8,261 @ $26.97 2026-10-27 — Venrock Healthcare Capital Partners III, L.P. · bought 8,729 @ $25.84 2026-10-27 — Venrock Healthcare Capital Partners III, L.P. · bought 31,067 @ $26.84
2026-10-232026-10-27

Insider cost basis

Share-weighted average price across 6 reported purchases, with the full range of prices paid. Purchases only — averaging a sale into an "insider cost" would describe a price nobody paid.

$18.00 $26.97
$18.41 weighted average insider purchase price

Insider participation

One row per insider, one cell per reported transaction, shaded by value. Repeat buying and activity clustered in time are visible at a glance.

Venrock Healthcare Capital Partners III, L.P. 10% owner
Included with a free account

The analysis built on top of these filings

The filings above are public record and stay public here. What an account adds for $LYCA is the reading of them — and for this company, that is what the list below says it is, no more.

  • Insider cost basisShare-weighted average price paid across the 6 reported purchases, with the full range, against the current price.
  • Insider participationWho bought, how often, and how the buying is distributed across the people filing — one person repeating is not several agreeing.
  • Transaction timelineThe [{'transaction_date': '2026-10-27', 'insider_name': 'Venrock Healthcare Capital Partners III, L.P.', 'insider_title': '10% owner', 'transaction_type': 'Open-market buy', 'shares': 8729.0, 'price': 25.84, 'value': 225557.36, 'is_buy': True}, {'transaction_date': '2026-10-27', 'insider_name': 'Venrock Healthcare Capital Partners III, L.P.', 'insider_title': '10% owner', 'transaction_type': 'Open-market buy', 'shares': 31067.0, 'price': 26.84, 'value': 833838.28, 'is_buy': True}, {'transaction_date': '2026-10-26', 'insider_name': 'Venrock Healthcare Capital Partners III, L.P.', 'insider_title': '10% owner', 'transaction_type': 'Open-market buy', 'shares': 1944444.0, 'price': 18.0, 'value': 34999992.0, 'is_buy': True}, {'transaction_date': '2026-10-26', 'insider_name': 'Venrock Healthcare Capital Partners III, L.P.', 'insider_title': '10% owner', 'transaction_type': 'Open-market buy', 'shares': 8261.0, 'price': 26.97, 'value': 222799.17, 'is_buy': True}, {'transaction_date': '2026-10-23', 'insider_name': 'Venrock Healthcare Capital Partners III, L.P.', 'insider_title': '10% owner', 'transaction_type': 'Open-market buy', 'shares': 24560.0, 'price': 25.68, 'value': 630700.8, 'is_buy': True}, {'transaction_date': '2026-10-23', 'insider_name': 'Venrock Healthcare Capital Partners III, L.P.', 'insider_title': '10% owner', 'transaction_type': 'Open-market buy', 'shares': 28379.0, 'price': 26.11, 'value': 740975.69, 'is_buy': True}] reported transactions plotted over the window rather than listed, so concentration is visible.

Not available for LYCA today: no research case — nothing here has cleared the scoring threshold. Both appear on this page on their own if that changes.

A free account opens all of it.

Not financial advice. This page reports public filings and past research output. It is not a recommendation to buy or sell, and no price target here is a prediction. Trade at your own risk.